| Dr Lucia Fernanda Reyes, MD | |
|
222 Ashville Ave Ste 10, Cary, NC 27518-6130 | |
| (919) 350-7231 | |
| Not Available |
| Full Name | Dr Lucia Fernanda Reyes |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 8 Years |
| Location | 222 Ashville Ave Ste 10, Cary, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013363514 | NPI | - | NPPES |
| 103357200 | Medicaid | FL |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wakemed, Raleigh Campus | Raleigh, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wake Specialty Physicians Llc | 7416006085 | 144 |
News Archive
ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that is has received guidance in writing from the U.S. Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of ARYx's novel anticoagulant agent, tecarfarin (ATI-5923).
Researchers from CNRS, INSERM and Toulouse University Hospital have demonstrated how the parasite Plasmodium falciparum, which causes severe forms of malaria, is able to circumvent the action of artemisinin and its derivatives, which are today the first-line drugs used to treat this disease. This study supplies some important findings that will enable a clearer understanding of the mechanisms of resistance to antimalarial drugs and the testing of novel therapeutic strategies in a context where the drug resistance of parasites is of increasing concern.
Johns Hopkins and Yale scientists have found that melanoma cells use a cloaking protein to hide from immune cells poised to attack the cancer. Nearly 40 percent of their sampling of melanoma tissues contained the B7-H1 protein, also called PD-L1, and scientists say it could be used as a target for new therapies.
Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.
Machine learning (or coding) could help reduce false positives from mammography screening, according to an article study published online in the May 4, 2017 issue of the Journal of the American Medical Association Oncology.
› Verified 9 days ago
| Entity Name | Wake Specialty Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942440375 PECOS PAC ID: 7416006085 Enrollment ID: O20090601000520 |
News Archive
ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that is has received guidance in writing from the U.S. Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of ARYx's novel anticoagulant agent, tecarfarin (ATI-5923).
Researchers from CNRS, INSERM and Toulouse University Hospital have demonstrated how the parasite Plasmodium falciparum, which causes severe forms of malaria, is able to circumvent the action of artemisinin and its derivatives, which are today the first-line drugs used to treat this disease. This study supplies some important findings that will enable a clearer understanding of the mechanisms of resistance to antimalarial drugs and the testing of novel therapeutic strategies in a context where the drug resistance of parasites is of increasing concern.
Johns Hopkins and Yale scientists have found that melanoma cells use a cloaking protein to hide from immune cells poised to attack the cancer. Nearly 40 percent of their sampling of melanoma tissues contained the B7-H1 protein, also called PD-L1, and scientists say it could be used as a target for new therapies.
Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.
Machine learning (or coding) could help reduce false positives from mammography screening, according to an article study published online in the May 4, 2017 issue of the Journal of the American Medical Association Oncology.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lucia Fernanda Reyes, MD 222 Ashville Ave Ste 10, Cary, NC 27518-6130 Ph: (919) 235-6575 | Dr Lucia Fernanda Reyes, MD 222 Ashville Ave Ste 10, Cary, NC 27518-6130 Ph: (919) 350-7231 |
News Archive
ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that is has received guidance in writing from the U.S. Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of ARYx's novel anticoagulant agent, tecarfarin (ATI-5923).
Researchers from CNRS, INSERM and Toulouse University Hospital have demonstrated how the parasite Plasmodium falciparum, which causes severe forms of malaria, is able to circumvent the action of artemisinin and its derivatives, which are today the first-line drugs used to treat this disease. This study supplies some important findings that will enable a clearer understanding of the mechanisms of resistance to antimalarial drugs and the testing of novel therapeutic strategies in a context where the drug resistance of parasites is of increasing concern.
Johns Hopkins and Yale scientists have found that melanoma cells use a cloaking protein to hide from immune cells poised to attack the cancer. Nearly 40 percent of their sampling of melanoma tissues contained the B7-H1 protein, also called PD-L1, and scientists say it could be used as a target for new therapies.
Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.
Machine learning (or coding) could help reduce false positives from mammography screening, according to an article study published online in the May 4, 2017 issue of the Journal of the American Medical Association Oncology.
› Verified 9 days ago
Dr. Fred Scott Rabon, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 Sas Campus Dr, Cary, NC 27513 Phone: 919-531-9004 Fax: 919-654-3800 | |
Dr. Mrinalini Sujala Kodumagulla, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1831 Lake Pine Dr Ste 200, Cary, NC 27511 Phone: 919-380-1849 Fax: 919-380-1851 | |
Daniel C Richard, MD Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 600 New Waverly Pl, Ste 203, Cary, NC 27518 Phone: 919-859-5650 Fax: 919-859-5695 | |
Mrs. Claudia Lucia Gomez, FNP-BC Family Medicine Medicare: Medicare Enrolled Practice Location: 540 New Waverly Pl Ste 200, Cary, NC 27518 Phone: 919-954-4159 Fax: 919-954-4445 | |
Essie Lee, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1515 Sw Cary Pkwy, Cary, NC 27511 Phone: 919-387-3180 | |
Dr. Michael D Gagliardi, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 540 Waverly Place, Suite 200, Cary, NC 27511 Phone: 919-954-4159 |